18755-56-1

Usage

Uses

Used in Pharmaceutical and Fine Chemicals Production:
2-(4-Aminophenyl)-2-methylpropan-1-ol is used as a key intermediate for the synthesis of various pharmaceuticals and fine chemicals. Its unique structure allows for the development of new compounds with potential therapeutic applications.
Used as a Chiral Building Block:
In the field of chiral chemistry, 2-(4-Aminophenyl)-2-methylpropan-1-ol serves as a chiral building block for the synthesis of chiral pharmaceutical compounds. Its enantioselective properties are valuable in creating enantiomerically pure substances, which are essential for the pharmaceutical industry.
Used in the Development of New Materials:
2-(4-Aminophenyl)-2-methylpropan-1-ol has potential applications in the development of new materials due to its aromatic properties and reactivity. It can be incorporated into the design and synthesis of novel materials with specific properties for various applications.
Used as a Reagent in Asymmetric Synthesis Reactions:
In asymmetric synthesis, 2-(4-Aminophenyl)-2-methylpropan-1-ol is utilized as a reagent to achieve enantioselective reactions, leading to the formation of chiral compounds with high enantiomeric purity. This is crucial for the production of enantiomerically pure pharmaceuticals and other chiral compounds.
Used in Cosmetics and Personal Care Products:
Due to its aromatic properties, 2-(4-Aminophenyl)-2-methylpropan-1-ol is used as an ingredient in the production of cosmetics and personal care products. Its aromatic nature contributes to the fragrance and sensory experience of these products, enhancing their appeal to consumers.

InChI:InChI=1/C10H15NO/c1-10(2,7-12)8-3-5-9(11)6-4-8/h3-6,12H,7,11H2,1-2H3

Upstream product

• 2173-69-5 2-methyl-2-phenyl-propan-1-ol 
• 36924-81-9 ethyl 2-(4-aminophenyl)-2-methylpropanoate 
• 59115-08-1 methyl 2-methyl-2-(4-nitrophenyl)propanoate 
• 83397-45-9 ethyl 2-methyl-2-(4-nitrophenyl)propanoate 
• 18755-52-7 (2-acetoxy-1,1-dimethylethyl)benzene 
• 18755-53-8 2-methyl-2-(4-nitrophenyl)propan-1-ol 

Downstream Products

• 1258234-80-8 2-(4-((2S,5S)-2,5-bis(4-nitrophenyl)pyrrolidin-1-yl)phenyl)-2-methylpropan-1-ol 

Relevant academic research and scientific papers

Synthesis, biological evaluation and structure-activity relationship of novel dichloroacetophenones targeting pyruvate dehydrogenase kinases with potent anticancer activity

Pyruvate dehydrogenase kinases (PDKs) are promising therapeutic targets that have received increasing attentions in cancer metabolism. In this paper, we report the synthesis and biological evaluation of a series of novel dichloroacetophenones as potent PDKs inhibitors. Structure-activity relationship analysis enabled us to identify a potent compound 6u, which inhibited PDKs with an EC50 value of 0.09 μM, and reduced various cancer cells proliferation with IC50 values ranging from 1.1 to 3.8 μM, while show weak effect against non-cancerous L02 cell (IC50 > 10 μM). In the A375 xenograft model, 6u displayed an obvious antitumor activity at a dose of 5 mg/kg, but with no negative effect to the mice weight. Molecular docking suggested that 6u formed direct hydrogen bond interactions with Ser75 and Gln61 in PDK1, and meanwhile the aniline skeleton in 6u was sandwiched by the conserved hydrophobic residues Phe78 and Phe65, which contribute to the biochemical activity improvement. Moreover, 6u induced A375 cell apoptosis and cell arrest in G1 phase, and inhibited cancer cell migration. In addition, 6u altered glucose metabolic pathway in A375 cell by decreasing lactate formation and increasing ROS production and OCR consumption, which could serve as a potential modulator to reprogram the glycolysis pathway in cancer cell.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

IMIDAZOPYRAZINE SYK INHIBITORS

Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suf-fering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of an imidazopyrazine compound effective to reduce signs or symptoms of the disease or dis-order are provided.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.